MediGene AG (MDG1) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
74
About the Report
About the Report
Summary
MediGene AG (MediGene) is a biotechnology company which develops drugs for the treatment of various types and stages of cancer with candidates in clinical and pre-clinical development. The company focuses on the development of personalized T-cell-based immunotherapies. Its core business develops three immunotherapy platforms including DC vaccines to kill tumor cells; T-cell receptor (TCR) detects and kills tumor cells and T-cell-specific monoclonal antibodies (TAB's), helps to remove unwanted T cells from the body. MediGene also has one marketed drug, Veregen for the treatment of genital warts. The company has operational presence in US, Europe and Asia. Medigene is headquartered in Martinsried, Germany.
MediGene AG (MDG1)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
MediGene AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
MediGene AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
MediGene AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
MediGene AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
MediGene AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
MediGene AG, Pharmaceuticals & Healthcare, Deal Details 13
Private Equity 13
Cowen Healthcare Royalty Acquires Royalties Of Eligard From Medigene For USD 18 Million 13
Partnerships 14
Structured Immunity and Medigene Enter into Research Agreement 14
MediGene Enters into Research Agreement with RXi Pharma 15
Medigene Enters into Agreement with Max Delbruck Center for Molecular Medicine and Charite- Universitatsmedizin Berlin 16
Medigene Enters into Agreement with University of Lausanne 17
PharmaDerm and MediGene Enter into Agreement with Women's Choice Pharma 18
Medigene Enters Into Co Marketing Agreement With Kora Healthcare For Veregen 19
Medigene Enters Into Co-Marketing Agreement With Taurus Pharma For Veregen 20
Medigene Enters Into Co-Marketing Agreement With Nordic For Veregen, Genital Warts Drug 21
MediGene Enters Into Co-Development Agreement For EndoTAG-1 22
MediGene Enters Into Co-Marketing Agreement With Azanta For Veregen 23
Medigene Enters Into Co-Marketing Agreement With Bial For Veregen 24
Licensing Agreements 25
2A Pharma Enters into Licensing Agreement with MediGene 25
MediGene Expands Licensing Agreement with bluebird bio 26
Medigene Enters Into Licensing Agreement With Dr. Falk Pharma 27
Medigene Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Center 28
Trianta Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Centre for Molecular Medicine Berlin-Buch 29
MediGene Enters Into Licensing Agreement With SynCore Biotechnology For EndoTAG-1 30
MediGene Enters Into Licensing Agreement With Eczacibasi Ilac Pazarlama For Veregen 31
Medigene Enters Into Licensing Agreement With Difa Cooper For Veregen 32
MediGene Expands Licensing Agreement With Syncore Biotech For Veregen 33
Equity Offering 34
Medigene Raises USD37.9 Million in Private Placement of Shares 34
Medigene to Raise USD18.8 Million in Private Placement of Shares 35
Medigene Raises USD22.6 Million in Private Placement of Shares 37
Medigene Raises USD52 Million in Rights Offering of Shares 38
Medigene Raises USD20.3 Million in Rights Offering of Securities 40
Asset Transactions 41
Fougera Pharma Acquires US Rights to Veregen from Medigene 41
SynCore Biotech to Acquire Rights to EndoTAG-1 from MediGene 42
Acquisition 43
Tongyang Networks Acquires 29.72% Stake in MediGene for USD28 Million 43
Medigene Sells Minority Stake in Immunocore 44
Amgen to Acquire Catherex from Medigene 45
Medigene Acquires Trianta Immunotherapies 46
MediGene AG-Key Competitors 47
MediGene AG-Key Employees 48
MediGene AG-Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Recent Developments 50
Financial Announcements 50
May 09, 2018: Medigene reports First Quarter 2018 financials and provides operational update 50
Mar 22, 2018: Medigene publishes 2017 annual report 52
Nov 09, 2017: Medigene Reports Nine Months' Results 2017 55
Aug 03, 2017: Medigene Reports Results of First Six Months 2017 57
May 11, 2017: Medigene Reports Results Of First Quarter 2017 58
Mar 23, 2017: Medigene publishes its 2016 annual report and outlook for 2017 60
Corporate Communications 62
Sep 03, 2018: Medi gene an nounces change in ex ec ut ive lead er ship team 62
Apr 11, 2018: Medigene appoints Dr. Kai Pinkernell to the Executive Management Board as CMO/CDO 63
Aug 08, 2017: Medigene announces formation of new Scientific Advisory Board 64
May 11, 2017: Dave Lemus Steps Down As COO And Continues Cooperation In An Advisory Role 65
Product News 66
08/30/2017: Medigene Presents Automated Platform For Tcr Identification At Car-Tcr Summit 66
08/28/2017: Medigene presents approaches for improving selection of neoantigens for use in cancer immunotherapy 67
08/25/2017: Medigene Announces Participation At Five Upcoming Scientific And Investor Conferences 69
08/16/2017: Medigene Presents Posters on Immunotherapies at CRI-CIMT-EATI-AACR Conference 70
06/08/2017: Medigene and Academic Partners Publish a Method to Enhance Adoptive T-cell Therapies 71
04/04/2017: Academic Partner Presented Compassionate Use Data On AML DC Vaccine At AACR Conference 72
03/23/2017: Medigene: Announces target and outlines design for its first clinical trial in TCR cancer immunotherapy 73
Appendix 74
Methodology 74
About GlobalData 74
Contact Us 74
Disclaimer 74
List of Figure
List of Figures
MediGene AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
MediGene AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
MediGene AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
MediGene AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
MediGene AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
MediGene AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
List of Table
List of Tables
MediGene AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
MediGene AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
MediGene AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
MediGene AG, Deals By Therapy Area, 2012 to YTD 2018 10
MediGene AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Cowen Healthcare Royalty Acquires Royalties Of Eligard From Medigene For USD 18 Million 13
Structured Immunity and Medigene Enter into Research Agreement 14
MediGene Enters into Research Agreement with RXi Pharma 15
Medigene Enters into Agreement with Max Delbruck Center for Molecular Medicine and Charite- Universitatsmedizin Berlin 16
Medigene Enters into Agreement with University of Lausanne 17
PharmaDerm and MediGene Enter into Agreement with Women's Choice Pharma 18
Medigene Enters Into Co Marketing Agreement With Kora Healthcare For Veregen 19
Medigene Enters Into Co-Marketing Agreement With Taurus Pharma For Veregen 20
Medigene Enters Into Co-Marketing Agreement With Nordic For Veregen, Genital Warts Drug 21
MediGene Enters Into Co-Development Agreement For EndoTAG-1 22
MediGene Enters Into Co-Marketing Agreement With Azanta For Veregen 23
Medigene Enters Into Co-Marketing Agreement With Bial For Veregen 24
2A Pharma Enters into Licensing Agreement with MediGene 25
MediGene Expands Licensing Agreement with bluebird bio 26
Medigene Enters Into Licensing Agreement With Dr. Falk Pharma 27
Medigene Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Center 28
Trianta Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Centre for Molecular Medicine Berlin-Buch 29
MediGene Enters Into Licensing Agreement With SynCore Biotechnology For EndoTAG-1 30
MediGene Enters Into Licensing Agreement With Eczacibasi Ilac Pazarlama For Veregen 31
Medigene Enters Into Licensing Agreement With Difa Cooper For Veregen 32
MediGene Expands Licensing Agreement With Syncore Biotech For Veregen 33
Medigene Raises USD37.9 Million in Private Placement of Shares 34
Medigene to Raise USD18.8 Million in Private Placement of Shares 35
Medigene Raises USD22.6 Million in Private Placement of Shares 37
Medigene Raises USD52 Million in Rights Offering of Shares 38
Medigene Raises USD20.3 Million in Rights Offering of Securities 40
Fougera Pharma Acquires US Rights to Veregen from Medigene 41
SynCore Biotech to Acquire Rights to EndoTAG-1 from MediGene 42
Tongyang Networks Acquires 29.72% Stake in MediGene for USD28 Million 43
Medigene Sells Minority Stake in Immunocore 44
Amgen to Acquire Catherex from Medigene 45
Medigene Acquires Trianta Immunotherapies 46
MediGene AG, Key Competitors 47
MediGene AG, Key Employees 48
MediGene AG, Subsidiaries 49
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.